ArticleBlood advances2020

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.

Thierry Facon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.